AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 JAN 25 - (NewsRx.com) -- Ampersand Medical Corp. (AMPM), Chicago, Illinois, announced the commencement of a clinical trial in China using the InPath System, a screening system for cervical cancer.
The trial is the first step in a larger effort to evaluate the efficacy of the InPath System for cervical-cancer screening. Principal investigators for the study include researchers from the Cleveland Clinic Foundation, the Chinese Academy of Medical Sciences, and Kaiser Permanente.
The InPath System is based on the use of biomolecular markers with fluorescent tags to identify abnormal cervical cells. This screening technology includes the use of multiple protein-based probes and stains used in combinations that can rapidly and inexpensively detect low-grade as well as high-grade dysplasia and cancer.
The pilot study for the Shanxi Province Cervical Screening Study (SPOCCS) II includes 200 patients and has been scheduled for completion in January 2001. The full-scale trial involving 9,000 women is expected to be completed by the middle of 2001.
The primary objective of SPOCCS II is to compare the sensitivity and specificity of the InPath System with the Pap test for screening for high-grade cervical dysplasia and cervical cancer. Another key objective is to compare the InPath System's ...